Results 231 to 240 of about 286,999 (386)

Dapagliflozin alleviates high‐fat‐induced obesity cardiomyopathy by inhibiting ferroptosis

open access: yesESC Heart Failure, Volume 12, Issue 2, Page 1358-1373, April 2025.
Abstract Aim: Dapagliflozin (Dapa) is a novel hypoglycaemic agent with multiple cardiovascular protective effects, and it is widely used in treatment of heart failure patients, but whether it can improve obese phenotype of heart failure and its mechanism is still unclear.
Di Chen   +7 more
wiley   +1 more source

Specific effects on kidneys relevant for performing a dietary cumulative risk assessment of pesticide residues. [PDF]

open access: yesEFSA J
European Food Safety Authority (EFSA)   +7 more
europepmc   +1 more source

Early diuretic response and outcome prediction in ambulatory worsening heart failure: Natriuresis versus diuresis

open access: yesESC Heart Failure, EarlyView.
Abstract Aims Early diuresis and natriuresis are commonly used to assess the efficacy of decongestive therapy following an acute heart failure episode. There is limited knowledge regarding which parameter better predicts adverse clinical outcomes, especially in the outpatient setting.
M. Cobo Marcos   +15 more
wiley   +1 more source

Association of baseline and longitudinal changes in insulin‐like growth factor‐binding protein‐7 with the risk of incident heart failure: Data from the PREVEND study

open access: yesEuropean Journal of Heart Failure, EarlyView.
Insulin‐like growth factor‐binding protein‐7 (IGFBP7) and heart failure (HF) risk: the PREVEND study. CI, confidence interval; HR, hazard ratio. Abstract Aim Senescence is a major risk factor for heart failure (HF), and insulin‐like growth factor‐binding protein‐7 (IGFBP7) has been identified as an important senescence‐inducing factor.
Sabrina Abou Kamar   +9 more
wiley   +1 more source

Flow-dependent transport processes 2024: filtration, absorption, and secretion. [PDF]

open access: yesAm J Physiol Renal Physiol
Edwards A, McDonough AA, Ellison DH.
europepmc   +1 more source

Current and novel biomarkers in cardiogenic shock

open access: yesEuropean Journal of Heart Failure, EarlyView.
A summary of current and novel biomarkers and their potential stages of release in cardiogenic shock. The diagram illustrates the proposed release of the biomarkers during the different stages of cardiogenic shock: progression from cardiac dysfunction/stress, through to inflammation and end‐organ dysfunction.
Victor Galusko   +5 more
wiley   +1 more source

Home - About - Disclaimer - Privacy